JP2012508185A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508185A5
JP2012508185A5 JP2011534934A JP2011534934A JP2012508185A5 JP 2012508185 A5 JP2012508185 A5 JP 2012508185A5 JP 2011534934 A JP2011534934 A JP 2011534934A JP 2011534934 A JP2011534934 A JP 2011534934A JP 2012508185 A5 JP2012508185 A5 JP 2012508185A5
Authority
JP
Japan
Prior art keywords
pge
activity
compound
hematopoietic stem
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011534934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508185A (ja
JP5846915B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/063654 external-priority patent/WO2010054271A1/en
Publication of JP2012508185A publication Critical patent/JP2012508185A/ja
Publication of JP2012508185A5 publication Critical patent/JP2012508185A5/ja
Application granted granted Critical
Publication of JP5846915B2 publication Critical patent/JP5846915B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011534934A 2008-11-06 2009-11-06 造血幹細胞の生着手順を強化するための材料および方法 Expired - Fee Related JP5846915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11201808P 2008-11-06 2008-11-06
US61/112,018 2008-11-06
PCT/US2009/063654 WO2010054271A1 (en) 2008-11-06 2009-11-06 Materials and methds to enhance hematopoietic stem cells engraftment procedures

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015134076A Division JP6632822B2 (ja) 2008-11-06 2015-07-03 造血幹細胞の生着手順を強化するための材料および方法

Publications (3)

Publication Number Publication Date
JP2012508185A JP2012508185A (ja) 2012-04-05
JP2012508185A5 true JP2012508185A5 (cg-RX-API-DMAC7.html) 2012-12-20
JP5846915B2 JP5846915B2 (ja) 2016-01-20

Family

ID=42153284

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011534934A Expired - Fee Related JP5846915B2 (ja) 2008-11-06 2009-11-06 造血幹細胞の生着手順を強化するための材料および方法
JP2015134076A Expired - Fee Related JP6632822B2 (ja) 2008-11-06 2015-07-03 造血幹細胞の生着手順を強化するための材料および方法
JP2017195168A Withdrawn JP2018048156A (ja) 2008-11-06 2017-10-05 造血幹細胞の生着手順を強化するための材料および方法
JP2019217044A Withdrawn JP2020063263A (ja) 2008-11-06 2019-11-29 造血幹細胞の生着手順を強化するための材料および方法
JP2023001015A Pending JP2023052244A (ja) 2008-11-06 2023-01-06 造血幹細胞の生着手順を強化するための材料および方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015134076A Expired - Fee Related JP6632822B2 (ja) 2008-11-06 2015-07-03 造血幹細胞の生着手順を強化するための材料および方法
JP2017195168A Withdrawn JP2018048156A (ja) 2008-11-06 2017-10-05 造血幹細胞の生着手順を強化するための材料および方法
JP2019217044A Withdrawn JP2020063263A (ja) 2008-11-06 2019-11-29 造血幹細胞の生着手順を強化するための材料および方法
JP2023001015A Pending JP2023052244A (ja) 2008-11-06 2023-01-06 造血幹細胞の生着手順を強化するための材料および方法

Country Status (10)

Country Link
US (5) US9107909B2 (cg-RX-API-DMAC7.html)
EP (3) EP3031907B1 (cg-RX-API-DMAC7.html)
JP (5) JP5846915B2 (cg-RX-API-DMAC7.html)
CN (4) CN102245758A (cg-RX-API-DMAC7.html)
AU (4) AU2009313290B2 (cg-RX-API-DMAC7.html)
CA (3) CA3203374A1 (cg-RX-API-DMAC7.html)
ES (1) ES2845641T3 (cg-RX-API-DMAC7.html)
PT (1) PT3031907T (cg-RX-API-DMAC7.html)
WO (1) WO2010054271A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201804932B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883507B2 (en) 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
SG10201803982TA (en) 2008-05-16 2018-07-30 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
US8784825B2 (en) 2008-08-28 2014-07-22 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
EP3031907B1 (en) 2008-11-06 2021-01-06 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
CN103167876B (zh) * 2010-08-12 2016-08-31 菲特治疗公司 改进的造血干细胞和祖细胞疗法
PL2663313T3 (pl) * 2011-01-13 2019-01-31 SciPharm S.à r.l. Sposób zwiększania wszczepiania hematopoetycznych komórek macierzystych
CA2850484C (en) 2011-09-30 2021-01-26 Bluebird Bio, Inc. Compounds for improved viral transduction
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
CN104066837B (zh) 2011-12-02 2020-12-08 菲特治疗公司 增强的干细胞组合物
WO2013130499A1 (en) * 2012-02-29 2013-09-06 University Of Virginia Patent Foundation Compositions and methods for cxcr4 signaling and umbilical cord blood stem cell engraftment
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
JP6285930B2 (ja) * 2012-07-20 2018-02-28 タイガ バイオテクノロジーズ,インク. 造血コンパートメントの再構築及び自家再構築の増進
US20150216903A1 (en) * 2012-08-10 2015-08-06 Bluebird Bio, Inc. Compounds for improved viral transduction
WO2014134539A1 (en) 2013-02-28 2014-09-04 President And Fellows Of Harvard College Methods and compositions for mobilizing stem cells
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US9943545B2 (en) * 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
EP4091609A1 (en) 2013-04-29 2022-11-23 Medregen, LLC Wound healing via autologous stem cell mobilization
KR101489861B1 (ko) * 2013-05-07 2015-02-05 경북대학교 산학협력단 Amd3100을 포함하는 골질환 예방 또는 치료용 조성물
CA2974903A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
CN104774806B (zh) * 2015-04-09 2019-02-15 广州赛莱拉干细胞科技股份有限公司 一种胎盘造血干细胞的制备方法
BR112018001232A2 (pt) 2015-07-21 2018-09-25 The Children's Medical Center Corporation pd-l1 que expressa células-tronco hematopoéticas e usos
CN108883136A (zh) 2016-02-12 2018-11-23 蓝鸟生物公司 Vcn增强子组合物及其使用方法
KR20250134722A (ko) 2016-02-12 2025-09-11 블루버드 바이오, 인코포레이티드. Vcn 인핸서 조성물 및 이의 사용 방법
WO2017147610A1 (en) * 2016-02-26 2017-08-31 President And Fellows Of Harvard College Highly engraftable hematopoietic stem cells
US20200224165A1 (en) * 2016-07-22 2020-07-16 Senlin Li Methods and compositions for rejuvenation
US10583156B2 (en) 2016-12-02 2020-03-10 Taiga Biotechnologies, Inc. Nanoparticle formulations
AU2018212854B2 (en) 2017-01-27 2024-06-20 Children's Hospital Medical Center Methods of enhancing engraftment activity of hematopoietic stem cells
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US11213546B2 (en) 2017-09-07 2022-01-04 Emory University Methods to mobilize tissue resident cells for adoptive t cell therapy
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
FR3074189A1 (fr) * 2017-11-30 2019-05-31 Assistance Publique - Hopitaux De Paris Methode de generation de greffons de cellules souches hematopoietiques
CN108404112B (zh) * 2018-04-01 2020-05-12 北京诺赛启研再生医学研究院有限公司 提高造血干细胞归巢及植入率的方法及其试剂
EP3647413A1 (en) * 2018-10-31 2020-05-06 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas O.A., M.P. (CIEMAT) Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation
EP3952909A4 (en) 2019-04-08 2023-06-07 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR CRYOPRESERVING IMMUNE CELLS
SG11202112529WA (en) 2019-05-14 2021-12-30 Taiga Biotechnologies Inc Compositions and methods for treating t cell exhaustion
JP7543395B2 (ja) 2020-03-31 2024-09-02 デンカ株式会社 アルミナ粉末、樹脂組成物、及び放熱部品
CN116509834B (zh) * 2023-01-20 2025-05-13 东北师范大学 化合物在制备造血干/祖细胞增殖和损伤修复药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
JPH08205860A (ja) * 1994-01-21 1996-08-13 Usa Government 造血細胞の膨大化および移植方法
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
CA2462628C (en) * 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
EP1461087A1 (en) * 2001-12-06 2004-09-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
EP1471818A4 (en) * 2002-02-04 2007-03-28 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISEASES USING 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137 , 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 OR 13249 MOLECULES
JP4865541B2 (ja) 2003-04-08 2012-02-01 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 化学誘引物質に対する増大させた感受性を有する幹細胞およびそれを産生および使用する方法
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2006001463A1 (ja) * 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. S1p受容体結合能を有する化合物およびその用途
US20080021078A1 (en) 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
WO2007041511A2 (en) * 2005-09-30 2007-04-12 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
JP2007099724A (ja) 2005-10-06 2007-04-19 Shizuoka Prefecture スルファチドを標的とした抗ウイルス剤
US8076315B2 (en) * 2005-10-14 2011-12-13 The Board Of Trustees Of The University Of Illinois Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
EP1999255A2 (en) * 2006-03-24 2008-12-10 The Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
WO2007148332A1 (en) 2006-06-22 2007-12-27 Yeda Resaerch And Development Co. Ltd Catecholamine receptor modulation
EP3824885A1 (en) 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
EP2094839B1 (en) * 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
US8598328B2 (en) 2006-12-13 2013-12-03 National University Corporation Nagoya University Tol1 factor transposase and DNA introduction system using the same
EP3031907B1 (en) 2008-11-06 2021-01-06 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
EP3533445A1 (en) 2009-03-19 2019-09-04 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
CA2850484C (en) 2011-09-30 2021-01-26 Bluebird Bio, Inc. Compounds for improved viral transduction

Similar Documents

Publication Publication Date Title
Schiattarella et al. Nitrosative stress drives heart failure with preserved ejection fraction
JP6632822B2 (ja) 造血幹細胞の生着手順を強化するための材料および方法
US20210077505A1 (en) Method to enhance tissue regeneration
US11690837B2 (en) Methods of improving cell-based therapy
US20060223863A1 (en) Methods for treating Hepatitis C
RU2009131454A (ru) Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств
RU2011149256A (ru) Пестицидные композиции
JP2014012726A (ja) キサンチン酸化還元酵素阻害剤を使用する腎機能保持方法
JP2002509881A (ja) Cd11/cd18接着レセプター媒介疾患の治療用アンタゴニスト
EP1676574A2 (en) Methods for promoting survival of transplanted tissues and cells
RU2008134423A (ru) Новые производные пиридина
JP2014502979A5 (cg-RX-API-DMAC7.html)
US12351609B2 (en) Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload
Leclere et al. C-linked antifreeze glycoprotein (C-AFGP) analogues as novel cryoprotectants
RU2008128347A (ru) Новые конденсированные производные пиррола
BR112018006866B1 (pt) Compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
NZ596820A (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
Kandhi et al. EETs promote hypoxic pulmonary vasoconstriction via constrictor prostanoids
Hamada et al. Novel BACE1 inhibitors possessing a 5-nitroisophthalic scaffold at the P2 position
Zhou et al. In Silico Observation of the Conformational Opening of the Glutathione-Binding Site of Microsomal Prostaglandin E2 Synthase‑1
Chan et al. Protective effects of histamine on Gq-mediated relaxation in regenerated endothelium
JP7658909B2 (ja) 筋ジストロフィー治療薬
US20140065706A1 (en) Materials and methods for mobilizing cells including cd34+, hematopoietic colony forming, and endothelial colony forming cells
Amann et al. Eicosanoid release in the endotoxin-primed isolated perfused rat lung and its pharmacological modification
CN104341362B (zh) 三氮唑磺酰丙二酸类化合物、其制备方法及用途